Celltrion is not new to the US biosimilars market. For years, the company has partnered with other leading firms – including Pfizer and Teva – to market its biosimilars in the US, notching up achievements that have included launching the first US biosimilar monoclonal antibody, with Inflectra (infliximab-dyyb), as well as offering the first Rituxan (rituximab) rival to boast a key rheumatoid arthritis indication. (Also see "Teva And Celltrion Gain Arthritis Advantage On Rituximab" - Generics Bulletin, 6 May, 2020.)
However, a significant change is now on the horizon for Celltrion, as it transitions to a direct sales model for...
